We use our own and third-party cookies to optimize your experience on this site, including to maintain user sessions. Without these cookies our site will not function well. If you continue browsing our site we take that to mean that you understand and accept how we use the cookies. If you wish to decline our cookies we will redirect you to Google.
Already have an account? Sign in.

 Remember Me | Forgot Your Password?

Shiseido Gains Access To Canadian Life Sciences Company's Hair-Regenerative Technology

May 30, 2013: 12:00 AM EST
Shiseido signed a collaboration and technology transfer deal with Canada-based life sciences company RepliCel Life Sciences Inc. As part of the agreement, Shiseido gains access to RepliCel's hair regenerative medicine technology. Shiseido said it plans to combine RepliCel's technology with its own in order to develop and commercialize safe and effective hair regenerative medicine that combines beauty and medical science to help those with baldness and thinning hair. With its safety guaranteed by RepliCel's more than 10 years of clinical research, the autologous cell implantation technology replicates the patient's own cells and injects them into the balding scalp to rejuvenate hair growth. RepliCel's technology offers several advantages, including small physical burden during surgeries, long-lasting effects, and fewer risks of reactions.
"Shiseido starts research on hair regenerative medicine", Shiseido, May 30, 2013, © Shiseido Co.,Ltd.
Companies, Organizations
Deals, M&A, JVs, Licensing
Innovation & New Ideas
Press Release
Research, Studies, Advice
Developed by Yuri Ingultsov Software Lab.